ArticleOncotarget2016
miR-129-3p controls centrosome number in metastatic prostate cancer cells by repressing CP110.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Exploring the role of long non-coding RNAs in renal cell carcinoma: insights into signaling pathways.Cancer cell international · 2025Review
- The ncRNA-AURKA Interaction in Hepatocellular Carcinoma: Insights into Oncogenic Pathways, Therapeutic Opportunities, and Future Challenges.Life (Basel, Switzerland) · 2024Review
- lncRNA XIST/miR‑129‑2‑3p axis targets CCP110 to regulate the proliferation, invasion and migration of endometrial cancer cells.Experimental and therapeutic medicine · 2023Article
- Circular RNA coiled-coil domain containing 66 regulates malignant development of papillary thyroid carcinoma by upregulating La ribonucleoprotein 1Bioengineered · 2022Article
- MicroRNA miR-425 promotes tumor progression by inhibiting Dickkopf-related protein-3 in gastric cancer.Bioengineered · 2021Article
- Centrosome amplification: a quantifiable cancer cell trait with prognostic value in solid malignancies.Cancer metastasis reviews · 2021Review
- MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.Journal of cellular and molecular medicine · 2020Article
- Effects of miR-129-3p on biological functions of prostate cancer cells through targeted regulation of Smad3.Oncology letters · 2020Article
- MiR-425 Promotes Migration and Invasion in Bladder Cancer by Targeting Dickkopf 3.Journal of Cancer · 2020Article
- Overcome cancer drug resistance by targeting epigenetic modifications of centrosome.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Adaptively capturing the heterogeneity of expression for cancer biomarker identification.BMC bioinformatics · 2018Article
- miR‑539 suppresses proliferation and induces apoptosis in renal cell carcinoma by targeting high mobility group A2.Molecular medicine reports · 2018Article
- MALAT1 promotes osteosarcoma development by regulation of HMGB1 via miR-142-3p and miR-129-5p.Cell cycle (Georgetown, Tex.) · 2017Article
- MicroRNAs and epithelial-mesenchymal transition in prostate cancer.Oncotarget · 2016Review
- MicroRNA-144 Suppresses Prostate Cancer Growth and Metastasis by Targeting EZH2.Technology in cancer research & treatmentArticle
- Emerging roles of DYRK2 in cancer.The Journal of biological chemistryReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 3 countries.
Funding
Abstract
The centrosome plays a key role in cancer invasion and metastasis. However, it is unclear how abnormal centrosome numbers are regulated when prostate cancer (PCa) cells become metastatic. CP110 was previously described for its contribution of centrosome amplification (CA) and early development of aggressive cell behaviour. However its regulation in metastatic cells remains unclear. Here we identified miR-129-3p as a novel metastatic microRNA. CP110 was identified as its target protein. In PCa cells that have metastatic capacity, CP110 expression was repressed by miR-129-3p. High miR-129-3p expression levels increased cell invasion, while increasing CP110 levels decreased cell invasion. Overexpression of CP110 in metastatic PCa cells resulted in a decrease in the number of metastasis. In tissues of PCa patients, low CP110 and high miR-129-3p expression levels correlated with metastasis, but not with the expression of genes related to EMT. Furthermore, overexpression of CP110 in metastatic PCa cells resulted in excessive-CA (E-CA), and a change in F-actin distribution which is in agreement with their reduced metastatic capacity. Our data demonstrate that miR-129-3p functions as a CA gatekeeper in metastatic PCa cells by maintaining pro-metastatic centrosome amplification (CA) and preventing anti-metastatic E-CA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.